RUNX2 and osteosarcoma: In related research, the same team also revealed that RUNX2 inhibits the transcriptional and pro-apoptotic activities of p53 through functional collaboration with HDAC6 in human osteosarcoma, potentially implicating a role for RUNX2 in Adriamycin resistance in this cancer type [178].